<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460875</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-07033</org_study_id>
    <secondary_id>NCI-2011-03121</secondary_id>
    <nct_id>NCT01460875</nct_id>
    <nct_alias>NCT00634127</nct_alias>
  </id_info>
  <brief_title>Recombinant Interferon Alfa-2b in Treating Patients With Melanoma</brief_title>
  <official_title>Pilot Study of IFN-alpha-2b Dose Reduction With Dose Optimization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Carson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies recombinant interferon alfa-2b in treating patients with
      melanoma. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and
      slow the growth of melanoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether selection of the optimal IFN-alpha-2b (recombinant interferon
      alfa-2b) dose can be made using signal transduction data.

      SECONDARY OBJECTIVES:

      I. To determine the tolerability of adjuvant IFN-alpha-2b administered at an optimized dose
      in terms of the toxicities that are observed and the ability of patients to receive a full
      year of therapy.

      II. The transcription of a panel of IFN-alpha-induced genes previously identified by
      microarray analysis will be determined by Real-Time reverse transcriptase-polymerase chain
      reaction (RT PCR) in order that the correlation between signal transducer and activator of
      transcription 1 (STAT1) phosphorylation and IFN-alpha gene regulation can be evaluated.

      III. Microarray analysis of patient peripheral blood mononuclear cells (PBMCs) will be used
      to evaluate the effect of dose-reduction on IFN-alpha gene expression.

      IV. In order to define the clinical role of tumor sensitivity to IFN-alpha, patient tumor
      biopsies taken prior to the administration of IFN-alpha will be systematically evaluated for
      cellular levels of janus kinase (Jak)-STAT signaling intermediates.

      OUTLINE:

      Patients receive recombinant interferon alfa-2b subcutaneously (SC) thrice weekly. Treatment
      continues for 11 months in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3-6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2008</start_date>
  <completion_date type="Actual">January 5, 2014</completion_date>
  <primary_completion_date type="Actual">January 5, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of Activated STAT1(Phospho-STAT1)</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Mean and 95% confidence interval will be summarized for phospho-STAT1 at a lower dose and the standard dose. The phospho-STAT1 will also be compared between the dose levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Determine the tolerability of adjuvant IFN-α-2b administered at an optimized dose in terms of the toxicities that are observed and the ability of patients to receive a full year of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Correlation Between STAT1 Phosphorylation and Interferon Alfa Gene Regulation</measure>
    <time_frame>Prior to treatment and 1 and 4 hours post therapy on day 1 every other week during the first 12 weeks, and then every 3 months</time_frame>
    <description>Levels of p-STAT1 in PBMCs were analyzed just prior to IFN-a-2b administration to determine levels that remained stable or increased over the course of dose reduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Dose-reduction on Expression of Interferon Alfa Stimulated Genes</measure>
    <time_frame>1 hour post therapy</time_frame>
    <description>Evaluated using microarray analysis of patient PBMCs. Compared using the Wilcoxon signed rank test for the dose 10MU/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Dose-reduction on Interferon Alfa Gene Expression</measure>
    <time_frame>1 hour post therapy</time_frame>
    <description>Evaluated using microarray analysis of patient PBMCs. Compared using the Wilcoxon signed rank test for the dose 4MU/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Dose-reduction on Interferon Alfa Gene Expression Through Marker CD69</measure>
    <time_frame>4 hours post therapy</time_frame>
    <description>Evaluated using microarray analysis of patient PBMCs. Compared between doses using the Wilcoxon signed rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Dose-reduction on Interferon Alfa Gene Expression at Dose Level 4MU</measure>
    <time_frame>4 hours post therapy</time_frame>
    <description>Evaluated using microarray analysis of patient PBMCs. Compared between doses using the Wilcoxon signed rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Role of Tumor Sensitivity to Recombinant Interferon Alfa-2b Using Cellular Levels of Jak-STAT Signaling Intermediates</measure>
    <time_frame>Baseline and every other week prior to recombinant interferon alfa-2b administration</time_frame>
    <description>Define the clinical role of tumor sensitivity to IFN-α, patient tumor biopsies taken prior to the administration of IFN-α will be systematically evaluated for cellular levels of Jak-STAT signaling intermediates.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Stage IA Skin Melanoma</condition>
  <condition>Stage IB Skin Melanoma</condition>
  <condition>Stage IIA Skin Melanoma</condition>
  <condition>Stage IIB Skin Melanoma</condition>
  <condition>Stage IIC Skin Melanoma</condition>
  <condition>Stage IIIA Skin Melanoma</condition>
  <condition>Stage IIIB Skin Melanoma</condition>
  <condition>Stage IIIC Skin Melanoma</condition>
  <condition>Stage IV Skin Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment (interferon therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa-2b</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (interferon therapy)</arm_group_label>
    <other_name>Alfatronol</other_name>
    <other_name>Glucoferon</other_name>
    <other_name>Heberon Alfa</other_name>
    <other_name>IFN alpha-2B</other_name>
    <other_name>Intron A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
    <arm_group_label>Treatment (interferon therapy)</arm_group_label>
    <other_name>Correlative studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be considered a candidate for adjuvant IFN-alpha-2b therapy after having
             undergone successful surgery for high-risk melanoma (Breslow thickness &gt; 4 mm or lymph
             node disease) or complete resection of metastatic disease; definitive surgery should
             have been accomplished no greater than 90 days prior to start of treatment with
             intravenous IFN-alpha-2b

          -  Patients must have completed 20 treatments of intravenous IFN-alpha-2b according to
             standard practice within 2 months of beginning treatment on this study

          -  Patients must have not have any evidence of persistent or recurrent disease as
             determined by the appropriate radiologic imaging techniques

          -  Patients may have received prior IFN-alpha therapy for metastatic disease, but more
             than 6 months must have passed between the last dose of IFN-alpha therapy for
             metastatic disease and the first dose of intravenous IFN-alpha-2b; patients who have
             had prior interleukin (IL)-2 are eligible for this study

          -  Patients may have received radiation therapy after intravenous IFN-alpha-2b; they may
             begin subcutaneous dosing of IFN-alpha-2b on this study after the radiation therapy
             has been completed; the patient may initiate dose reductions after the last radiation
             treatment as long as the appropriate amount of time has passed

          -  Life expectancy of greater than 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 70%)

          -  Leukocytes &gt;= 3,000/ul

          -  Absolute neutrophil count &gt;= 1,500/ul

          -  Platelets &gt;= 100,000/ul

          -  Total bilirubin =&lt; 2.0 (Gilbert's disease permitted)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) &lt;
             3 x institutional upper limit of normal

          -  Creatinine =&lt; 1.5 and stable OR

          -  Creatinine clearance &gt;= 60 mL.min/1.73 m^2 for patients with creatinine levels above
             normal

          -  Pulse oximetry &gt;= 90% on room air at rest

          -  Serum pregnancy test negative

          -  The effects of interferon alpha-2b on the developing human fetus at the recommended
             therapeutic dose are unknown; for this reason, and because interferons are known to be
             teratogenic, women of child-bearing potential and men must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation; should a woman become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             treating physician immediately

          -  All patients must be informed of the investigational nature of this study and must
             provide written informed consent in accordance with institutional and federal
             guidelines; a copy of the informed consent document signed by the patient must be
             given to the patient

        Exclusion Criteria:

          -  Patients may not be receiving any investigational agents

          -  History of allergic reactions attributed to compounds that are similar to interferon
             alpha-2b

          -  Patients known to be positive for human immunodeficiency virus (HIV), Hepatitis B
             surface antigen (HbsAg) or hepatitis C antibody

          -  Patients with organ allografts or immunodeficiency syndromes

          -  Patients with prior malignancies may participate provided they have been free of
             disease for at least 2 years except for tumors with a negligible risk for metastasis
             or death, such as adequately controlled basal cell carcinoma or squamous-cell
             carcinoma of the skin or carcinoma in situ of the cervix

          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements; a history of depression in and of itself is not an exclusion to
             going participating provided the patient and physician believe the depression is
             controlled and the patient will discontinue the IFN-alpha should symptoms recur

          -  Pregnant women are excluded from this study because interferon alpha-2b is an agent
             with the potential for teratogenic or abortifacient effects; because there is an
             unknown but potential risk for adverse events in nursing infants secondary to
             treatment of the mother with IFN-alpha, breastfeeding should be discontinued if the
             mother is treated with IFN-alpha

          -  Prisoners will be excluded due to the need for multiple timed visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Carson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer@osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <results_first_submitted>May 4, 2018</results_first_submitted>
  <results_first_submitted_qc>October 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2018</results_first_posted>
  <last_update_submitted>October 31, 2018</last_update_submitted>
  <last_update_submitted_qc>October 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>William Carson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>high risk melanoma</keyword>
  <keyword>lymph node disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Interferon Therapy)</title>
          <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Interferon Therapy)</title>
          <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="22" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Level of Activated STAT1(Phospho-STAT1)</title>
        <description>Mean and 95% confidence interval will be summarized for phospho-STAT1 at a lower dose and the standard dose. The phospho-STAT1 will also be compared between the dose levels.</description>
        <time_frame>up to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Interferon Therapy)</title>
            <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Activated STAT1(Phospho-STAT1)</title>
          <description>Mean and 95% confidence interval will be summarized for phospho-STAT1 at a lower dose and the standard dose. The phospho-STAT1 will also be compared between the dose levels.</description>
          <units>MU/m2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose I (10 MU/m2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.96" lower_limit="0.31" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose II (4 MU/m2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="0.11" upper_limit="21.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The method to be developed will allow us to declare that a response at a lower dose is not inferior to that at the standard dose for a particular patient, using a patient specific inferiority test.</non_inferiority_desc>
            <p_value>.22</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>Determine the tolerability of adjuvant IFN-α-2b administered at an optimized dose in terms of the toxicities that are observed and the ability of patients to receive a full year of therapy.</description>
        <time_frame>up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Interferon Therapy)</title>
            <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>Determine the tolerability of adjuvant IFN-α-2b administered at an optimized dose in terms of the toxicities that are observed and the ability of patients to receive a full year of therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Correlation Between STAT1 Phosphorylation and Interferon Alfa Gene Regulation</title>
        <description>Levels of p-STAT1 in PBMCs were analyzed just prior to IFN-a-2b administration to determine levels that remained stable or increased over the course of dose reduction.</description>
        <time_frame>Prior to treatment and 1 and 4 hours post therapy on day 1 every other week during the first 12 weeks, and then every 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Interferon Therapy)</title>
            <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Correlation Between STAT1 Phosphorylation and Interferon Alfa Gene Regulation</title>
          <description>Levels of p-STAT1 in PBMCs were analyzed just prior to IFN-a-2b administration to determine levels that remained stable or increased over the course of dose reduction.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Dose-reduction on Expression of Interferon Alfa Stimulated Genes</title>
        <description>Evaluated using microarray analysis of patient PBMCs. Compared using the Wilcoxon signed rank test for the dose 10MU/m2</description>
        <time_frame>1 hour post therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Interferon Therapy)</title>
            <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Dose-reduction on Expression of Interferon Alfa Stimulated Genes</title>
          <description>Evaluated using microarray analysis of patient PBMCs. Compared using the Wilcoxon signed rank test for the dose 10MU/m2</description>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SOCS1-1 hour post 10MU-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.6" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OAS1-1 hour post 10MU-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.5" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL10-1 hour post 10MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="0.2" upper_limit="5128.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD69-1 hour post 10MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.4" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Dose-reduction on Interferon Alfa Gene Expression</title>
        <description>Evaluated using microarray analysis of patient PBMCs. Compared using the Wilcoxon signed rank test for the dose 4MU/m2</description>
        <time_frame>1 hour post therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Interferon Therapy)</title>
            <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Dose-reduction on Interferon Alfa Gene Expression</title>
          <description>Evaluated using microarray analysis of patient PBMCs. Compared using the Wilcoxon signed rank test for the dose 4MU/m2</description>
          <units>fold increase</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SOCS1-1 hour post 4MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.4" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OAS1-1 hour post 4MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.5" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL10-1 hour post 4MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="0.0" upper_limit="386.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD69-1 hour post 4MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.4" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Dose-reduction on Interferon Alfa Gene Expression Through Marker CD69</title>
        <description>Evaluated using microarray analysis of patient PBMCs. Compared between doses using the Wilcoxon signed rank test.</description>
        <time_frame>4 hours post therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Interferon Therapy)</title>
            <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Dose-reduction on Interferon Alfa Gene Expression Through Marker CD69</title>
          <description>Evaluated using microarray analysis of patient PBMCs. Compared between doses using the Wilcoxon signed rank test.</description>
          <units>fold increase</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SOCS1- 4 hour post-10MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.6" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OAS1-4 hour post -10MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.5" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL10-4 hour post- 10MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="0.2" upper_limit="5128.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD69-4 hour post- 10MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.4" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Dose-reduction on Interferon Alfa Gene Expression at Dose Level 4MU</title>
        <description>Evaluated using microarray analysis of patient PBMCs. Compared between doses using the Wilcoxon signed rank test.</description>
        <time_frame>4 hours post therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Interferon Therapy)</title>
            <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Dose-reduction on Interferon Alfa Gene Expression at Dose Level 4MU</title>
          <description>Evaluated using microarray analysis of patient PBMCs. Compared between doses using the Wilcoxon signed rank test.</description>
          <units>fold increase</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SOCS1-4 hour post 4MU-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.4" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OAS1-4 hour post 4MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0.4" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL10-4 hour post 4MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.9" lower_limit="0.0" upper_limit="2898.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD69-4 hour post 4MU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.4" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Role of Tumor Sensitivity to Recombinant Interferon Alfa-2b Using Cellular Levels of Jak-STAT Signaling Intermediates</title>
        <description>Define the clinical role of tumor sensitivity to IFN-α, patient tumor biopsies taken prior to the administration of IFN-α will be systematically evaluated for cellular levels of Jak-STAT signaling intermediates.</description>
        <time_frame>Baseline and every other week prior to recombinant interferon alfa-2b administration</time_frame>
        <population>Data was not collected and analyzed for outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Interferon Therapy)</title>
            <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Role of Tumor Sensitivity to Recombinant Interferon Alfa-2b Using Cellular Levels of Jak-STAT Signaling Intermediates</title>
          <description>Define the clinical role of tumor sensitivity to IFN-α, patient tumor biopsies taken prior to the administration of IFN-α will be systematically evaluated for cellular levels of Jak-STAT signaling intermediates.</description>
          <population>Data was not collected and analyzed for outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Interferon Therapy)</title>
          <description>Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
recombinant interferon alfa-2b: Given SC
laboratory biomarker analysis: Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelosuppression</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased AST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte Abnormalities</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropsychiatric Systems</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Mylosuppression</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased AST</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte Abnormalities</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropsychiatric Symptoms</sub_title>
                <description>including depression</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Carson, MD</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-293-6306</phone>
      <email>William.Carson@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

